TerraPower Isotopes announces cGMP manufacturing facility

TerraPower Isotopes announced that the company is building its flagship current Good Manufacturing Practices (cGMP) actinium-225 (ac-225) manufacturing facility in the Bellwether District of Philadelphia, Pennsylvania. TPI’s development of an East Coast manufacturing facility, along with expanding capacity in its existing Everett, Washington will increase production capacity 20-fold and position the company as the premier global distributor of ac-225. The project features a multi-year buildout, with production of cGMP actinium-225 beginning in 2029.

“TerraPower’s mission is to deliver new technologies to market that can improve lives; and the work our TerraPower Isotopes team is doing shows real promise in supporting the expansion of a diverse suite of cancer treatments using nuclear medicine,” said TerraPower president and CEO Chris Levesque. “This new facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments.”

“Today marks a major milestone for TerraPower Isotopes and for the future of precision medicine. This new facility is a testament to the demand for actinium-225 as part of the growing industry which is transforming how cancer is treated,” said Scott Claunch, president of TerraPower Isotopes. “Our team is proud to be building a large-scale cGMP manufacturing facility in Philadelphia, which will play a pivotal role in expanding global access to this rare isotope.”

TPI evaluated over 350 potential sites across the United States in a rigorous site selection process that included 49 site visits in eight metropolitan areas. The Bellwether District is uniquely positioned to offer the scale, proximity to critical infrastructure, and access to a robust life sciences and medical ecosystem that is critical to TPI and the radiopharmaceutical industry.

Supporter Statements
“TerraPower Isotopes’ presence in Philadelphia will strengthen a place where health, science, and technology converge to address some of the world’s most pressing challenges. The city has a long history of turning ideas and discoveries into advances that accelerate progress, and TerraPower Isotopes’ arrival brings new expertise and momentum to the region’s dynamic research community. – Kevin B. Mahoney, Chief Executive Officer, University of Pennsylvania Health System

“Philadelphia continues to solidify its position as a premier hub for advanced therapies. This milestone highlights the depth of the region’s life sciences ecosystem and its expanding role in advancing innovation in nuclear medicine and radiopharmaceutical development. By establishing a presence here, the TPI team will benefit from a highly collaborative ecosystem that will meaningfully support the company’s growth trajectory.” - Sumit Verma, Co-founder, Orchestra Life Sciences

“TPI’s Actinium-225 is already enabling clinical programs around the world as a key component of next-generation targeted alpha therapies. We congratulate them on this important milestone, as this new facility represents a critical step in expanding and strengthening the infrastructure required to accelerate the transformation of cancer treatments.” - Jaap Duiker, Managing Director, Von Gahlen